Leitlinie zur Diagnostik und Therapie von Patienten mit chronisch obstruktiver Bronchitis und Lungenemphysem (COPD)^[*]

Zusammenfassung

Das vorliegende Dokument ist eine Neufassung und Aktualisierung der Leitlinie zur Diagnostik und Therapie von Patienten mit COPD, die die bisherige Version aus dem Jahr 2007 ablöst. Die Fülle an neuen Erkenntnissen zu Risikofaktoren, Diagnostik, Schweregradeinschätzung, Prävention und medikamentösen sowie nicht medikamentösen Therapiemaßnahmen machten eine umfassende Überarbeitung erforderlich. Die neue Leitlinie baut auf das GOLD-Dokument unter Berücksichtigung von Besonderheiten in Deutschland und Österreich auf.

Abstract

This document is a revision of the guideline for diagnosis and treatment of COPD that replaces the version from 2007. A multitude of recent reports regarding risk factors, diagnosis, assessment, prevention and pharmacological as well as non-pharmacological treatment options made a major revision mandatory. The new guideline is based on the GOLD document taking into account specifics in Germany and Austria.

^* Verabschiedet von den Vorständen der beteiligten Fachgesellschaften am 24. 01. 2018.

• Literatur

• 1 Vogelmeier C, Buhl R, Criée CP. et al. [Guidelines for the diagnosis and therapy of COPD issued by Deutsche Atemwegsliga and Deutsche Gesellschaft für Pneumologie und Beatmungsmedizin]. Pneumologie 2007; 61: e1-e40
• 2 Block LH, Burghuber OC, Hartl S. et al. [Austrian Society for Pulmonary Diseases and Tuberculosis. Consensus concerning the management of chronic obstructive pulmonary diseases (COPD). Revised draft 2004]. Wiener klinische Wochenschrift 2004; 116: 268-278
• 3 Global Strategy for Diagnosis, Management, and Prevention of COPD. http://goldcopd.org/
• 4 www.AWMF.org
• 5 http://www.who.int
• 6 http://www.erswhitebook.org
• 7 Halbert RJ, Natoli JL, Gano A. et al. Global burden of COPD: systematic review and meta-analysis. Eur Respir J 2006; 28: 523-532
• 8 National Heart, Lung, and Blood Institute. Morbidity and mortality chartbook on cardiovascular, lung and blood diseases. Bethesda, Maryland: US Department of Health and Human Services, Public Health Service, National Institutes of Health. Accessed at: http://www.nhlbi.nih.gov/resources/docs/cht-book.htm; 2009
• 9 Buist AS, McBurnie MA, Vollmer WM. et al. International variation in the prevalence of COPD (the BOLD Study): a population-based prevalence study. Lancet 2007; 370: 741-750
• 10 Rycroft CE, Heyes A, Lanza L. et al. Epidemiology of chronic obstructive pulmonary disease: a literature review. Int J Chron Obstruct Pulmon Dis 2012; 7: 457-494
• 11 American Lung Association Epidemiology and Statistics Unit. Trends in COPD (Chronic Bronchitis and Emphysema): Morbidity and Mortality. Accessed at: http://www.lung.org/assets/documents/research/copd-trend-report.pdf. 2013
• 12 Murray CJ, Atkinson C, Bhalla K. et al. The state of US health, 1990-2010: burden of diseases, injuries, and risk factors. JAMA 2013; 310: 591-608
• 13 Kögler H, Metzdorf N, Glaab T. et al. Preselection of patients at risk for COPD by two simple screening questions. Respir Med 2010; 104: 1012-1019
• 14 Burgel PR. Chronic cough and sputum production: a clinical COPD phenotype?. Eur Respir J 2012; 40: 4-6
• 15 Thurlbeck WM, Müller NL. Emphysema: definition, imaging, and quantification. AJR Am J Roentgenol 1994; 163: 1017-1025
• 16 Quanjer PH, Stanojevic S, Cole TJ. et al. Multi-ethnic reference values for spirometry for the 3-95-yr age range: the global lung function 2012 equations. Eur Respir J 2012; 40: 1324-1343
• 17 Criée CP, Baur X, Berdel D. et al. [Standardization of spirometry: 2015 update. Published by German Atemwegsliga, German Respiratory Society and German Society of Occupational and Environmental Medicine]. Pneumologie 2015; 69: 147-164
• 18 Criée CP, Sorichter S, Smith HJ. et al. Body plethysmography – its principles and clinical use. Respir Med 2011; 105: 959-971
• 19 Enright MdP. Office-based DLCO tests help pulmonologists to make important clinical decisions. Respir Investig 2016; 54: 305-311
• 20 Woodruff PG, Barr RG, Bleecker E. et al. Clinical Significance of Symptoms in Smokers with Preserved Pulmonary Function. N Engl J Med 2016; 374: 1811-1821
• 21 Albert P, Agusti A, Edwards L. et al. Bronchodilator responsiveness as a phenotypic characteristic of established chronic obstructive pulmonary disease. Thorax 2012; 67: 701-708
• 22 Calverley PM, Albert P, Walker PP. Bronchodilator reversibility in chronic obstructive pulmonary disease: use and limitations. Lancet Respir Med 2013; 1: 564-573
• 23 Pothirat C, Chaiwong W, Phetsuk N. et al. Peak expiratory flow rate as a surrogate for forced expiratory volume in 1 second in COPD severity classification in Thailand. Int J Chron Obstruct Pulmon Dis 2015; 10: 1213-1218
• 24 Jackson H, Hubbard R. Detecting chronic obstructive pulmonary disease using peak flow rate: cross sectional survey. BMJ 2003; 327: 653-654
• 25 Nelson SB, LaVange LM, Nie Y. et al. Questionnaires and pocket spirometers provide an alternative approach for COPD screening in the general population. Chest 2012; 142: 358-366
• 26 Pellegrino R, Viegi G, Brusasco V. et al. Interpretative strategies for lung function tests. Eur Respir J 2005; 26: 948-968
• 27 Barjaktarevic I, Springmeyer S, Gonzalez X. et al. Diffusing capacity for carbon monoxide correlates best with tissue volume from quantitative CT scanning analysis. Chest 2015; 147: 1485-1493
• 28 German Society of Pneumology. recommendations for carrying out and evaluating stress tests in pneumology. Cardiorespiratory Interaction Section of the German Society of Pneumology]. Pneumologie 1998; 52: 225-231
• 29 ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories. ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med 2002; 166: 111-117
• 30 Lutchmedial SM, Creed WG, Moore AJ. et al. How Common Is Airflow Limitation in Patients With Emphysema on CT Scan of the Chest?. Chest 2015; 148: 176-184
• 31 Martinez FJ, Kotloff R. Prognostication in chronic obstructive pulmonary disease: implications for lung transplantation. Semin Respir Crit Care Med 2001; 22: 489-498
• 32 Jones PW. Issues concerning health-related quality of life in COPD. Chest 1995; 107: 187S-193S
• 33 Agusti A, Calverley PM, Celli B. et al. Characterisation of COPD heterogeneity in the ECLIPSE cohort. Respir Res 2010; 11: 122
• 34 Hurst JR, Vestbo J, Anzueto A. et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med 2010; 363: 1128-1138
• 35 Haughney J, Gruffydd-Jones K, Roberts J. et al. The distribution of COPD in UK general practice using the new GOLD classification. Eur Respir J 2014; 43: 993-1002
• 36 Vestbo J, Hurd SS, Agustí AG. et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2013; 187: 347-365
• 37 Martinez FJ, Vestbo J, Anderson JA. et al. Effect of Fluticasone Furoate and Vilanterol on Exacerbations of Chronic Obstructive Pulmonary Disease in Patients with Moderate Airflow Obstruction. Am J Respir Crit Care Med 2017; 195: 881-888
• 38 Jones PW, Bosh TK. Quality of life changes in COPD patients treated with salmeterol. Am J Respir Crit Care Med 1997; 155: 1283-1289
• 39 Magnussen H, Disse B, Rodriguez-Roisin R. et al. Withdrawal of inhaled glucocorticoids and exacerbations of COPD. N Engl J Med 2014; 371: 1285-1294
• 40 Celli BR, Cote CG, Marin JM. et al. The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. N Engl J Med 2004; 350: 1005-1012
• 41 Puhan MA, Garcia-Aymerich J, Frey M. et al. Expansion of the prognostic assessment of patients with chronic obstructive pulmonary disease: the updated BODE index and the ADO index. Lancet 2009; 374: 704-711
• 42 Jones RC, Donaldson GC, Chavannes NH. et al. Derivation and validation of a composite index of severity in chronic obstructive pulmonary disease: the DOSE Index. Am J Respir Crit Care Med 2009; 180: 1189-1195
• 43 Divo M, Cote C, de Torres JP. et al. Comorbidities and risk of mortality in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2012; 186: 155-161
• 44 de Torres JP, Casanova C, Marín JM. et al. Prognostic evaluation of COPD patients: GOLD 2011 versus BODE and the COPD comorbidity index COTE. Thorax 2014; 69: 799-804
• 45 Agusti A, Sobradillo P, Celli B. Addressing the complexity of chronic obstructive pulmonary disease: from phenotypes and biomarkers to scale-free networks, systems biology, and P4 medicine. Am J Respir Crit Care Med 2011; 183: 1129-1137
• 46 Hughes JM, Pride NB. Examination of the carbon monoxide diffusing capacity (DL(CO)) in relation to its KCO and VA components. Am J Respir Crit Care Med 2012; 186: 132-139
• 47 Gevenois PA, De Vuyst P, de Maertelaer V. et al. Comparison of computed density and microscopic morphometry in pulmonary emphysema. Am J Respir Crit Care Med 1996; 154: 187-192
• 48 Tashkin DP, Altose MD, Bleecker ER. et al. The lung health study: airway responsiveness to inhaled methacholine in smokers with mild to moderate airflow limitation. The Lung Health Study Research Group. Am Rev Respir Dis 1992; 145: 301-310
• 49 http://ginasthma.org/asthma-copd-and-asthma-copd-overlap-syndrome-acos/
• 50 Vanfleteren LE, Kocks JW, Stone IS. et al. Moving from the Oslerian paradigm to the post-genomic era: are asthma and COPD outdated terms?. Thorax 2014; 69: 72-79
• 51 Tashkin DP, Chipps BE, Trudo F. et al. Fixed airflow obstruction in asthma: a descriptive study of patient profiles and effect on treatment responses. J Asthma 2014; 51: 603-609
• 52 Buffels J, Degryse J, Heyrman J. et al. Office spirometry significantly improves early detection of COPD in general practice: the DIDASCO Study. Chest 2004; 125: 1394-1399
• 53 Karsch M, Tilemann L, Schneider A. [Screening for COPD in primary care]. MMW Fortschr Med 2010; 152: 35-37
• 54 Sundblad BM, Larsson K, Nathell L. Lung function testing influences the attitude toward smoking cessation. Nicotine Tob Res 2010; 12: 37-42
• 55 Bize R, Burnand B, Mueller Y. et al. Biomedical risk assessment as an aid for smoking cessation. Cochrane Database Syst Rev 2012; 12: CD004705
• 56 Wilt TJ, Niewoehner D, Kim C. et al. Use of spirometry for case finding, diagnosis, and management of chronic obstructive pulmonary disease (COPD). Evid Rep Technol Assess (Summ) 2005; 121: 1-7
• 57 Siu AL, Bibbins-Domingo K. US Preventive Services Task Force (USPSTF). et al. Screening for Chronic Obstructive Pulmonary Disease: US Preventive Services Task Force Recommendation Statement. JAMA 2016; 315: 1372-1377
• 58 Anthonisen NR, Connett JE, Kiley JP. et al. Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1. The Lung Health Study. JAMA 1994; 272: 1497-1505
• 59 Burge PS, Calverley PM, Jones PW. et al. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ 2000; 320: 1297-1303
• 60 Pauwels RA, Löfdahl CG, Laitinen LA. et al. Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. European Respiratory Society Study on Chronic Obstructive Pulmonary Disease. N Engl J Med 1999; 340: 1948-1953
• 61 Vestbo J, Sørensen T, Lange P. et al. Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 1999; 353: 1819-1823
• 62 Al-Showair RA, Tarsin WY, Assi KH. et al. Can all patients with COPD use the correct inhalation flow with all inhalers and does training help?. Respir Med 2007; 101: 2395-2401
• 63 Voshaar T, App EM, Berdel D. et al. [Recommendations for the choice of inhalatory systems for drug prescription]. Pneumologie 2001; 55: 579-586
• 64 Ericsson CH, Svartengren K, Svartengren M. et al. Repeatability of airway deposition and tracheobronchial clearance rate over three days in chronic bronchitis. Eur Respir J 1995; 8: 1886-1893
• 65 Kim CS, Kang TC. Comparative measurement of lung deposition of inhaled fine particles in normal subjects and patients with obstructive airway disease. Am J Respir Crit Care Med 1997; 155: 899-905
• 66 Hay JG, Stone P, Carter J. et al. Bronchodilator reversibility, exercise performance and breathlessness in stable chronic obstructive pulmonary disease. Eur Respir J 1992; 5: 659-664
• 67 Chrystyn H, Mulley BA, Peake MD. Dose response relation to oral theophylline in severe chronic obstructive airways disease. BMJ 1988; 297: 1506-1510
• 68 Gross NJ, Petty TL, Friedman M. et al. Dose response to ipratropium as a nebulized solution in patients with chronic obstructive pulmonary disease. A three-center study. . Am Rev Respir Dis 1989; 139: 1188-1191
• 69 OʼDriscoll BR, Kay EA, Taylor RJ. et al. A long-term prospective assessment of home nebulizer treatment. Respir Med 1992; 86: 317-325
• 70 Jenkins SC, Heaton RW, Fulton TJ. et al. Comparison of domiciliary nebulized salbutamol and salbutamol from a metered-dose inhaler in stable chronic airflow limitation. Chest 1987; 91: 804-807
• 71 Higgins BG, Powell RM, Cooper S. et al. Effect of salbutamol and ipratropium bromide on airway calibre and bronchial reactivity in asthma and chronic bronchitis. Eur Respir J 1991; 4: 415-420
• 72 Vathenen AS, Britton JR, Ebden P. et al. High-dose inhaled albuterol in severe chronic airflow limitation. Am Rev Respir Dis 1988; 138: 850-855
• 73 Disse B, Speck GA, Rominger KL. et al. Tiotropium (Spiriva): mechanistical considerations and clinical profile in obstructive lung disease. Life Sci 1999; 64: 457-464
• 74 COMBIVENT Inhalation Aerosol Study Group. In chronic obstructive pulmonary disease, a combination of ipratropium and albuterol is more effective than either agent alone. An 85-day multicenter trial. Chest 1994; 105: 1411-1419
• 75 Melani AS. Long-acting muscarinic antagonists. Expert Rev Clin Pharmacol 2015; 8: 479-501
• 76 Barr RG, Bourbeau J, Camargo CA. et al. Inhaled tiotropium for stable chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2005; 2: CD002876
• 77 Cheyne L, Irvin-Sellers MJ, White J. Tiotropium versus ipratropium bromide for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2013; 9: CD009552
• 78 Kesten S, Casaburi R, Kukafka D. et al. Improvement in self-reported exercise participation with the combination of tiotropium and rehabilitative exercise training in COPD patients. Int J Chron Obstruct Pulmon Dis 2008; 3: 127-136
• 79 Tashkin DP, Celli B, Senn S. et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. Engl J Med 2008; 359: 1543-1554
• 80 Vogelmeier C, Hederer B, Glaab T. et al. Tiotropium versus salmeterol for the prevention of exacerbations of COPD. N Engl J Med 2011; 364: 1093-1103
• 81 Decramer ML, Chapman KR, Dahl R. et al. Once-daily indacaterol versus tiotropium for patients with severe chronic obstructive pulmonary disease (INVIGORATE): a randomised, blinded, parallel-group study. Lancet Respir Med 2013; 1: 524-533
• 82 Jones PW, Singh D, Bateman ED. et al. Efficacy and safety of twice-daily aclidinium bromide in COPD patients: the ATTAIN study. Eur Respir J 2012; 40: 830-836
• 83 Beier J, Kirsten AM, Mróz R. et al. Efficacy and safety of aclidinium bromide compared with placebo and tiotropium in patients with moderate-to-severe chronic obstructive pulmonary disease: results from a 6-week, randomized, controlled Phase IIIb study. COPD 2013; 10: 511-522
• 84 Kerwin E, Hébert J, Gallagher N. et al. Efficacy and safety of NVA237 versus placebo and tiotropium in patients with COPD: the GLOW2 study. Eur Respir J 2012; 40: 1106-1114
• 85 Anthonisen NR, Connett JE, Enright PL. et al. Hospitalizations and mortality in the Lung Health Study. Am J Respir Crit Care Med 2002; 166: 333-339
• 86 Michele TM, Pinheiro S, Iyasu S. The safety of tiotropium – the FDAʼs conclusions. N Engl J Med 2010; 363: 1097-1099
• 87 Beasley R, Singh S, Loke YK. et al. Call for worldwide withdrawal of tiotropium Respimat mist inhaler. BMJ 2012; 345: e7390
• 88 Wise RA, Anzueto A, Cotton D. et al. Tiotropium Respimat inhaler and the risk of death in COPD. N Engl J Med 2013; 369: 1491-1501
• 89 van Schayck CP, Folgering H, Harbers H. et al. Effects of allergy and age on responses to salbutamol and ipratropium bromide in moderate asthma and chronic bronchitis. Thorax 1991; 46: 355-359
• 90 Campbell M, Eliraz A, Johansson G. et al. Formoterol for maintenance and as-needed treatment of chronic obstructive pulmonary disease. Respir Med 2005; 99: 1511-1520
• 91 Calverley PM, Anderson JA, Celli B. et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007; 356: 775-789
• 92 Cazzola M, Matera MG, Santangelo G. et al. Salmeterol and formoterol in partially reversible severe chronic obstructive pulmonary disease: a dose-response study. Respir Med 1995; 89: 357-362
• 93 Rossi A, Kristufek P, Levine BE. et al. Comparison of the efficacy, tolerability, and safety of formoterol dry powder and oral, slow-release theophylline in the treatment of COPD. Chest 2002; 121: 1058-1069
• 94 Ulrik CS. Efficacy of inhaled salmeterol in the management of smokers with chronic obstructive pulmonary disease: a single centre randomised, double blind, placebo controlled, crossover study. Thorax 1995; 50: 750-754
• 95 Tashkin DP, Fabbri LM. Long-acting beta-agonists in the management of chronic obstructive pulmonary disease: current and future agents. Respir Res 2010; 11: 149
• 96 Donohue JF, Fogarty C, Lötvall J. et al. Once-daily bronchodilators for chronic obstructive pulmonary disease: indacaterol versus tiotropium. Am J Respir Crit Care Med 2010; 182: 155-162
• 97 Kornmann O, Dahl R, Centanni S. et al. Once-daily indacaterol versus twice-daily salmeterol for COPD: a placebo-controlled comparison. Eur Respir J 2011; 37: 273-279
• 98 Cazzola M, Imperatore F, Salzillo A. et al. Cardiac effects of formoterol and salmeterol in patients suffering from COPD with preexisting cardiac arrhythmias and hypoxemia. Chest 1998; 114: 411-415
• 99 Khoukaz G, Gross NJ. Effects of salmeterol on arterial blood gases in patients with stable chronic obstructive pulmonary disease. Comparison with albuterol and ipratropium. Am J Respir Crit Care Med 1999; 160: 1028-1030
• 100 Polverino E, Gómez FP, Manrique H. et al. Gas exchange response to short-acting beta2-agonists in chronic obstructive pulmonary disease severe exacerbations. Am J Respir Crit Care Med 2007; 176: 350-355
• 101 Chapman KR, Rennard SI, Dogra A. et al. Long-term safety and efficacy of indacaterol, a long-acting β₂-agonist, in subjects with COPD: a randomized, placebo-controlled study. Chest 2011; 140: 68-75
• 102 McKay SE, Howie CA, Thomson AH. et al. Value of theophylline treatment in patients handicapped by chronic obstructive lung disease. Thorax 1993; 48: 227-232
• 103 Murciano D, Auclair MH, Pariente R. et al. A randomized, controlled trial of theophylline in patients with severe chronic obstructive pulmonary disease. N Engl J Med 1989; 320: 1521-1525
• 104 Taylor DR, Buick B, Kinney C. et al. The efficacy of orally administered theophylline, inhaled salbutamol, and a combination of the two as chronic therapy in the management of chronic bronchitis with reversible air-flow obstruction. Am Rev Respir Dis 1985; 131: 747-751
• 105 Williamson BH, Milligan G, Griffiths K. et al. An assessment of major and minor side effects of theophylline. Aust: NZJ Med; 1988
• 106 Zhou Y, Wang X, Zeng X. et al. Positive benefits of theophylline in a randomized, double-blind, parallel-group, placebo-controlled study of low-dose, slow-release theophylline in the treatment of COPD for 1 year. Respirology 2006; 11: 603-610
• 107 ZuWallack RL, Mahler DA, Reilly D. et al. Salmeterol plus theophylline combination therapy in the treatment of COPD. Chest 2001; 119: 1661-1670
• 108 Cosío BG, Shafiek H, Iglesias A. et al. Oral Low-dose Theophylline on Top of Inhaled Fluticasone-Salmeterol Does Not Reduce Exacerbations in Patients With Severe COPD: A Pilot Clinical Trial. Chest 2016; 150: 123-130
• 109 Vogelmeier C, Kardos P, Harari S. et al. Formoterol mono- and combination therapy with tiotropium in patients with COPD: a 6-month study. Respir Med 2008; 102: 1511-1520
• 110 Rabe KF, Timmer W, Sagkriotis A. et al. Comparison of a combination of tiotropium plus formoterol to salmeterol plus fluticasone in moderate COPD. Chest 2008; 134: 255-262
• 111 van Noord JA, de Munck DR, Bantje TA. et al. Long-term treatment of chronic obstructive pulmonary disease with salmeterol and the additive effect of ipratropium. Eur Respir J 2000; 15: 878-885
• 112 Bateman ED, Ferguson GT, Barnes N. et al. Dual bronchodilation with QVA149 versus single bronchodilator therapy: the SHINE study. Eur Respir J 2013; 42: 1484-1494
• 113 D'Urzo AD, Rennard SI, Kerwin EM. et al. Efficacy and safety of fixed-dose combinations of aclidinium bromide/formoterol fumarate: the 24-week, randomized, placebo-controlled AUGMENT COPD study. Respir Res 2014; 15: 123
• 114 Singh D, Jones PW, Bateman ED. et al. Efficacy and safety of aclidinium bromide/formoterol fumarate fixed-dose combinations compared with individual components and placebo in patients with COPD (ACLIFORM-COPD): a multicentre, randomised study. BMC Pulm Med 2014; 14: 178
• 115 Farne HA, Cates CJ. Long-acting beta2-agonist in addition to tiotropium versus either tiotropium or long-acting beta2-agonist alone for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2015; 10: CD008989
• 116 van der Molen T, Cazzola M. Beyond lung function in COPD management: effectiveness of LABA/LAMA combination therapy on patient-centred outcomes. Prim Care Respir J 2012; 21: 101-108
• 117 Mahler DA, Decramer M, D'Urzo A. et al. Dual bronchodilation with QVA149 reduces patient-reported dyspnoea in COPD: the BLAZE study. Eur Respir J 2014; 43: 1599-1609
• 118 Singh D, Ferguson GT, Bolitschek J. et al. Tiotropium + olodaterol shows clinically meaningful improvements in quality of life. Respir Med 2015; 109: 1312-1319
• 119 Bateman ED, Chapman KR, Singh D. et al. Aclidinium bromide and formoterol fumarate as a fixed-dose combination in COPD: pooled analysis of symptoms and exacerbations from two six-month, multicentre, randomised studies (ACLIFORM and AUGMENT). Respir Res 2015; 16: 92
• 120 Wedzicha JA, Decramer M, Ficker JH. et al. Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomised, double-blind, parallel-group study. Lancet Respir Med 2013; 1: 199-209
• 121 Wedzicha JA, Banerji D, Chapman KR. et al. Indacaterol-Glycopyrronium versus Salmeterol-Fluticasone for COPD. N Engl J Med 2016; 374: 2222-2234
• 122 Boardman C, Chachi L, Gavrila A. et al. Mechanisms of glucocorticoid action and insensitivity in airways disease. Pulm Pharmacol Ther 2014; 29: 129-143
• 123 Barnes PJ. New anti-inflammatory targets for chronic obstructive pulmonary disease. Nat Rev Drug Discov 2013; 12: 543-559
• 124 Yang IA, Clarke MS, Sim EH. et al. Inhaled corticosteroids for stable chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2012; 7: CD002991
• 125 Vestbo J, Anderson JA, Brook RD. et al. Fluticasone furoate and vilanterol and survival in chronic obstructive pulmonary disease with heightened cardiovascular risk (SUMMIT): a double-blind randomised controlled trial. Lancet 2016; 387: 1817-1826
• 126 Worth H, Förster K, Eriksson G. et al. Budesonide added to formoterol contributes to improved exercise tolerance in patients with COPD. Respir Med 2010; 104: 1450-1459
• 127 Nannini LJ, Poole P, Milan SJ. et al. Combined corticosteroid and long-acting beta(2)-agonist in one inhaler versus inhaled corticosteroids alone for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2013; 8: CD006826
• 128 Vestbo J, Leather D, Diar Barkerly N. et al. Effectiveness of Fluticasone Furoate-Vilanterol for COPD in Clinical Practice. N Engl J Med 2016; 375: 1253-1260
• 129 Watz H, Tetzlaff K, Wouters EF. et al. Blood eosinophil count and exacerbations in severe chronic obstructive pulmonary disease after withdrawal of inhaled corticosteroids: a post-hoc analysis of the WISDOM trial. Lancet Respir Med 2016; 4: 390-398
• 130 Calverley PM, Stockley RA, Seemungal TA. et al. Reported pneumonia in patients with COPD: findings from the INSPIRE study. Chest 2011; 139: 505-512
• 131 Kew KM, Seniukovich A. Inhaled steroids and risk of pneumonia for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2014; 3: CD010115
• 132 Johnell O, Pauwels R, Löfdahl CG. et al. Bone mineral density in patients with chronic obstructive pulmonary disease treated with budesonide Turbuhaler. Eur Respir J 2002; 19: 1058-1063
• 133 Ferguson GT, Calverley PM, Anderson JA. et al. Prevalence and progression of osteoporosis in patients with COPD: results from the TOwards a Revolution in COPD Health study. Chest 2009; 136: 1456-1465
• 134 Suissa S, Kezouh A, Ernst P. Inhaled corticosteroids and the risks of diabetes onset and progression. Am J Med 2010; 123: 1001-1006
• 135 Wang JJ, Rochtchina E, Tan AG. et al. Use of inhaled and oral corticosteroids and the long-term risk of cataract. Ophthalmology 2009; 116: 652-657
• 136 Andréjak C, Nielsen R, Thomsen VØ. et al. Chronic respiratory disease, inhaled corticosteroids and risk of non-tuberculous mycobacteriosis. Thorax 2013; 68: 256-262
• 137 Dong YH, Chang CH, Lin WuFL. et al. Use of inhaled corticosteroids in patients with COPD and the risk of TB and influenza: A systematic review and meta-analysis of randomized controlled trials. A systematic review and meta-analysis of randomized controlled trials. Chest 2014; 145: 1286-1297
• 138 Lee CH, Kim K, Hyun MK. et al. Use of inhaled corticosteroids and the risk of tuberculosis. Thorax 2013; 68: 1105-1113
• 139 Nadeem NJ, Taylor SJ, Eldridge SM. Withdrawal of inhaled corticosteroids in individuals with COPD - a systematic review and comment on trial methodology. Respir Res 2011; 12: 107
• 140 van der Valk P, Monninkhof E, van der Palen J. et al. Effect of discontinuation of inhaled corticosteroids in patients with chronic obstructive pulmonary disease: the COPE study. Am J Respir Crit Care Med 2002; 166: 1358-1363
• 141 Wouters EF, Postma DS, Fokkens B. et al. Withdrawal of fluticasone propionate from combined salmeterol/fluticasone treatment in patients with COPD causes immediate and sustained disease deterioration: a randomised controlled trial. Thorax 2005; 60: 480-487
• 142 Kunz LI, Postma DS, Klooster K. et al. Relapse in FEV1 Decline After Steroid Withdrawal in COPD. Chest 2015; 148: 389-396
• 143 Vogelmeier C, Worth H, Buhl R. et al. "Real-life" inhaled corticosteroid withdrawal in COPD: a subgroup analysis of DACCORD. Int J Chron Obstruct Pulmon Dis 2017; 12: 487-494
• 144 Welte T, Miravitlles M, Hernandez P. et al. Efficacy and tolerability of budesonide/formoterol added to tiotropium in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2009; 180: 741-750
• 145 Singh D, Brooks J, Hagan G. et al. Superiority of “triple” therapy with salmeterol/fluticasone propionate and tiotropium bromide versus individual components in moderate to severe COPD. Thorax 2008; 63: 592-598
• 146 Hanania NA, Crater GD, Morris AN. et al. Benefits of adding fluticasone propionate/salmeterol to tiotropium in moderate to severe COPD. Respir Med 2012; 106: 91-101
• 147 Frith PA, Thompson PJ, Ratnavadivel R. et al. Glycopyrronium once-daily significantly improves lung function and health status when combined with salmeterol/fluticasone in patients with COPD: the GLISTEN study, a randomised controlled trial. Thorax 2015; 70: 519-527
• 148 Siler TM, Kerwin E, Singletary K. et al. Efficacy and Safety of Umeclidinium Added to Fluticasone Propionate/Salmeterol in Patients with COPD: Results of Two Randomized, Double-Blind Studies. COPD 2016; 13: 1-10
• 149 Singh D, Papi A, Corradi M. et al. Single inhaler triple therapy versus inhaled corticosteroid plus long-acting β2-agonist therapy for chronic obstructive pulmonary disease (TRILOGY): a double-blind, parallel group, randomised controlled trial. Lancet 2016; 388: 963-973
• 150 Aaron SD, Vandemheen KL, Fergusson D. et al. Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial. Ann Intern Med 2007; 146: 545-555
• 151 Manson SC, Brown RE, Cerulli A. et al. The cumulative burden of oral corticosteroid side effects and the economic implications of steroid use. Respir Med 2009; 103: 975-994
• 152 Walters JA, Tan DJ, White CJ. et al. Systemic corticosteroids for acute exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2014; 9: CD001288
• 153 Fabbri LM, Calverley PM, Izquierdo-Alonso JL. et al. Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with longacting bronchodilators: two randomised clinical trials. Lancet 2009; 374: 695-703
• 154 Rabe KF. Update on roflumilast, a phosphodiesterase 4 inhibitor for the treatment of chronic obstructive pulmonary disease. Br J Pharmacol 2011; 163: 53-67
• 155 Martinez FJ, Calverley PM, Goehring UM. et al. Effect of roflumilast on exacerbations in patients with severe chronic obstructive pulmonary disease uncontrolled by combination therapy (REACT): a multicentre randomised controlled trial. Lancet 2015; 385: 857-866
• 156 Calverley PM, Rabe KF, Goehring UM. et al. Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials. Lancet 2009; 374: 685-694
• 157 Wouters EF, Bredenbröker D, Teichmann P. et al. Effect of the phosphodiesterase 4 inhibitor roflumilast on glucose metabolism in patients with treatment-naive, newly diagnosed type 2 diabetes mellitus. J Clin Endocrinol Metab 2012; 97: E1720-1725
• 158 White WB, Cooke GE, Kowey PR. et al. Cardiovascular safety in patients receiving roflumilast for the treatment of COPD. Chest 2013; 144: 758-765
• 159 Herath SC, Poole P. Prophylactic antibiotic therapy for chronic obstructive pulmonary disease (COPD). Cochrane Database Syst Rev 2013; 11: CD009764
• 160 Ni W, Shao X, Cai X. et al. Prophylactic use of macrolide antibiotics for the prevention of chronic obstructive pulmonary disease exacerbation: a meta-analysis. PloS one 2015; 10: e0121257
• 161 Seemungal TA, Wilkinson TM, Hurst JR. et al. Long-term erythromycin therapy is associated with decreased chronic obstructive pulmonary disease exacerbations. Am J Respir Crit Care Med 2008; 178: 1139-1147
• 162 Uzun S, Djamin RS, Kluytmans JA. et al. Azithromycin maintenance treatment in patients with frequent exacerbations of chronic obstructive pulmonary disease (COLUMBUS): a randomised, double-blind, placebo-controlled trial. Lancet Respir Med 2014; 2: 361-368
• 163 Albert RK, Connett J, Bailey WC. et al. Azithromycin for prevention of exacerbations of COPD. N Engl J Med 2011; 365: 689-698
• 164 Sethi S, Jones PW, Theron MS. et al. Pulsed moxifloxacin for the prevention of exacerbations of chronic obstructive pulmonary disease: a randomized controlled trial. Respir Res 2010; 11: 10
• 165 Survival and FEV1 decline in individuals with severe deficiency of alpha1-antitrypsin. The Alpha-1-Antitrypsin Deficiency Registry Study Group. Am J Respir Crit Care Med 1998; 158: 49-59
• 166 Seersholm N, Wencker M, Banik N. et al. Does alpha1-antitrypsin augmentation therapy slow the annual decline in FEV1 in patients with severe hereditary alpha1-antitrypsin deficiency? Wissenschaftliche Arbeitsgemeinschaft zur Therapie von Lungenerkrankungen (WATL) alpha1-AT study group. Eur Respir J 1997; 10: 2260-2263
• 167 Wencker M, Banik N, Buhl R. et al. Long-term treatment of alpha1-antitrypsin deficiency-related pulmonary emphysema with human alpha1-antitrypsin. Wissenschaftliche Arbeitsgemeinschaft zur Therapie von Lungenerkrankungen (WATL)-alpha1-AT-study group. Eur Respir J 1998; 11: 428-433
• 168 Chapman KR, Burdon JG, Piitulainen E. et al. Intravenous augmentation treatment and lung density in severe α1 antitrypsin deficiency (RAPID): a randomised, double-blind, placebo-controlled trial. Lancet 2015; 386: 360-368
• 169 Dirksen A, Piitulainen E, Parr DG. et al. Exploring the role of CT densitometry: a randomised study of augmentation therapy in alpha1-antitrypsin deficiency. Eur Respir J 2009; 33: 1345-1353
• 170 Stockley RA, Edgar RG, Pillai A. et al. Individualized lung function trends in alpha-1-antitrypsin deficiency: a need for patience in order to provide patient centered management?. Int J Chron Obstruct Pulmon Dis 2016; 11: 1745-1756
• 171 Allegra L, Cordaro CI, Grassi C. Prevention of acute exacerbations of chronic obstructive bronchitis with carbocysteine lysine salt monohydrate: a multicenter, double-blind, placebo-controlled trial. Respiration 1996; 63: 174-180
• 172 Guyatt GH, Townsend M, Kazim F. et al. A controlled trial of ambroxol in chronic bronchitis. Chest 1987; 92: 618-620
• 173 Petty TL. The National Mucolytic Study. Results of a randomized, double-blind, placebo-controlled study of iodinated glycerol in chronic obstructive bronchitis. Chest 1990; 97: 75-83
• 174 Worth H, Schacher C, Dethlefsen U. Concomitant therapy with Cineole (Eucalyptole) reduces exacerbations in COPD: a placebo-controlled double-blind trial. Respir Res 2009; 10: 69
• 175 Hansen NC, Skriver A, Brorsen-Riis L. et al. Orally administered N-acetylcysteine may improve general well-being in patients with mild chronic bronchitis. Respir Med 1994; 88: 531-535
• 176 British Thoracic Society Research Committee. Oral N-acetylcysteine and exacerbation rates in patients with chronic bronchitis and severe airways obstruction. Thorax 1985; 40: 832-835
• 177 Boman G, Bäcker U, Larsson S. et al. Oral acetylcysteine reduces exacerbation rate in chronic bronchitis: report of a trial organized by the Swedish Society for Pulmonary Diseases. Eur J Respir Dis 1983; 64: 405-415
• 178 Rasmussen JB, Glennow C. Reduction in days of illness after long-term treatment with N-acetylcysteine controlled-release tablets in patients with chronic bronchitis. Eur Respir J 1988; 1: 351-355
• 179 Tse HN, Raiteri L, Wong KY. et al. High-dose N-acetylcysteine in stable COPD: the 1-year, double-blind, randomized, placebo-controlled HIACE study. Chest 2013; 144: 106-118
• 180 Poole P, Black PN, Cates CJ. Mucolytic agents for chronic bronchitis or chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2012; 8: CD001287
• 181 Kardos P, Berck H, Fuchs KH. et al. [Guidelines of the german respiratory society for diagnosis and treatment of adults suffering from acute or chronic cough]. Pneumologie 2010; 64: 336-373
• 182 Irwin RS, Boulet LP, Cloutier MM. et al. Managing cough as a defense mechanism and as a symptom. A consensus panel report of the American College of Chest Physicians. Chest 1998; 114: 133S-181S
• 183 Barberà JA, Roger N, Roca J. et al. Worsening of pulmonary gas exchange with nitric oxide inhalation in chronic obstructive pulmonary disease. Lancet 1996; 347: 436-440
• 184 Jones AT, Evans TW. NO: COPD and beyond. Thorax 1997; 52: S16-521
• 185 Galiè N, Hoeper MM, Humbert M. et al. Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J 2009; 34: 1219-1263
• 186 Blanco I, Santos S, Gea J. et al. Sildenafil to improve respiratory rehabilitation outcomes in COPD: a controlled trial. Eur Respir J 2013; 42: 982-992
• 187 Goudie AR, Lipworth BJ, Hopkinson PJ. et al. Tadalafil in patients with chronic obstructive pulmonary disease: a randomised, double-blind, parallel-group, placebo-controlled trial. Lancet Respir Med 2014; 2: 293-300
• 188 Karner C, Cates CJ. Long-acting beta(2)-agonist in addition to tiotropium versus either tiotropium or long-acting beta(2)-agonist alone for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2012; 4: CD008989
• 189 Lange P, Marott JL, Vestbo J. et al. Prediction of the clinical course of chronic obstructive pulmonary disease, using the new GOLD classification: a study of the general population. Am J Respir Crit Care Med 2012; 186: 975-981
• 190 Agusti A, Edwards LD, Celli B. et al. Characteristics, stability and outcomes of the 2011 GOLD COPD groups in the ECLIPSE cohort. Eur Respir J 2013; 42: 636-646
• 191 Martinez FJ, Rabe KF, Sethi S. et al. Effect of Roflumilast and Inhaled Corticosteroid/Long-Acting β2-Agonist on Chronic Obstructive Pulmonary Disease Exacerbations (RE(2)SPOND). A Randomized Clinical Trial. Am J Respir Crit Care Med 2016; 194: 559-567
• 192 Anthonisen NR, Skeans MA, Wise RA. et al. The effects of a smoking cessation intervention on 14.5-year mortality: a randomized clinical trial. Ann Intern Med 2005; 142: 233-239
• 193 Andreas S, Batra A, Behr J. et al. [Guidelines for smoking cessation in patients with COPD issued by the Deutsche Gesellschaft für Pneumologie und Beatmungsmedizin]. Pneumologie 2008; 62: 255-272
• 194 Tønnesen P. Smoking cessation and COPD. Eur Respir Rev 2013; 22: 37-43
• 195 Lee PN, Fariss MW. A systematic review of possible serious adverse health effects of nicotine replacement therapy. Arch Toxicol 2017; 91: 1565-1594
• 196 McRobbie H, Bullen C, Hartmann-Boyce J. et al. Electronic cigarettes for smoking cessation and reduction. Cochrane Database Syst Rev 2014; 12: CD010216
• 197 Nowak D, Gohlke H, Hering T. et al. [Position paper of the German Respiratory Society (DGP) on electronic cigarettes (E-cigarettes) in cooperation with the following scientific societies and organisations: BVKJ, BdP, DGAUM, DGG, DGIM, DGK, DKG, DGSMP, GPP]. Pneumologie 2015; 69: 131-134
• 198 Tashkin DP, Rennard S, Hays JT. et al. Effects of varenicline on smoking cessation in patients with mild to moderate COPD: a randomized controlled trial. Chest 2011; 139: 591-599
• 199 Wilson DH, Wakefield MA, Steven ID. et al. “Sick of Smoking”: evaluation of a targeted minimal smoking cessation intervention in general practice. Med J Aust 1990; 152: 518-521
• 200 Kottke TE, Battista RN, DeFriese GH. et al. Attributes of successful smoking cessation interventions in medical practice. A meta-analysis of 39 controlled trials. JAMA 1988; 259: 2883-2889
• 201 Ockene JK, Kristeller J, Goldberg R. et al. Increasing the efficacy of physician-delivered smoking interventions: a randomized clinical trial. J Gen Intern Med 1991; 6: 1-8
• 202 McAfee T, Babb S, McNabb S. et al. Helping smokers quit – opportunities created by the Affordable Care Act. N Engl J Med 2015; 372: 5-7
• 203 Twardella D, Brenner H. Effects of practitioner education, practitioner payment and reimbursement of patients' drug costs on smoking cessation in primary care: a cluster randomised trial. Tob Control 2007; 16: 15-21
• 204 Eisner MD, Balmes J, Yelin EH. et al. Directly measured secondhand smoke exposure and COPD health outcomes. BMC Pulm Med 2006; 6: 12
• 205 Berufsgenossenschaftlicher Grundsatz für arbeitsmedizinische Vorsorgeuntersuchungen „G23 – obstruktive Atemwegserkrankungen. www.arbeitsschutzdigital.de
• 206 Woodhead M, Blasi F, Ewig S. et al. Guidelines for the management of adult lower respiratory tract infections. Eur Respir J 2005; 26: 1138-1180
• 207 Edwards KM, Dupont WD, Westrich MK. et al. A randomized controlled trial of cold-adapted and inactivated vaccines for the prevention of influenza A disease. J Infect Dis 1994; 169: 68-76
• 208 Hak E, van Essen GA, Buskens E. et al. Is immunising all patients with chronic lung disease in the community against influenza cost effective? Evidence from a general practice based clinical prospective cohort study in Utrecht, The Netherlands. J Epidemiol Community Health 1998; 52: 120-125
• 209 Poole PJ, Chacko E, Wood-Baker RW. et al. Influenza vaccine for patients with chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2000; 4: CD002733
• 210 Huang CL, Nguyen PA, Kuo PL. et al. Influenza vaccination and reduction in risk of ischemic heart disease among chronic obstructive pulmonary elderly. Comput Methods Programs Biomed 2013; 111: 507-511
• 211 Belongia EA, Sundaram ME, McClure DL. et al. Waning vaccine protection against influenza A (H3N2) illness in children and older adults during a single season. Vaccine 2015; 33: 246-251
• 212 Empfehlungen der Ständigen Impfkommission (STIKO) am Robert Koch-Institut – 2016/2017. Epi Bull. 29.08.2016 34.
• 213 STIKO. Aktualisierte Impfempfehlungen. Dtsch Ärzteblatt 2016; 39: A1706-1709
• 214 Wissenschaftliche Begründung für die Aktualisierung der Empfehlungen zur Indikationsimpfung gegen Pneumokokken für Risikogruppen. Epi Bull. 19.09.2016 37.
• 215 Ewig S, Höffken G, Kern WV. et al. [Management of Adult Community-acquired Pneumonia and Prevention – Update 2016]. Pneumologie 2016; 70: 151-200
• 216 Esposito S, Bonanni P, Maggi S. et al. Recommended immunization schedules for adults: Clinical practice guidelines by the Escmid Vaccine Study Group (EVASG), European Geriatric Medicine Society (EUGMS) and the World Association for Infectious Diseases and Immunological Disorders (WAidid). Hum Vaccin Immunother 2016; 12: 1777-1794
• 217 Tomczyk S, Bennett NM, Stoecker C. et al. Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among adults aged ≥65 years: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 2014; 63: 822-825
• 218 Bonten MJ, Huijts SM, Bolkenbaas M. et al. Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults. N Engl J Med 2015; 372: 1114-1125
• 219 van der Linden M, Falkenhorst G, Perniciaro S. et al. Effects of Infant Pneumococcal Conjugate Vaccination on Serotype Distribution in Invasive Pneumococcal Disease among Children and Adults in Germany. PLoS One 2015; 10: e0131494
• 220 Pletz MW, Ewig S, Heppner HJ. et al. [Position Paper on Adult Pneumococcal Vaccination: Position Paper of the German Respiratory Society and the German Geriatric Society]. Pneumologie 2015; 69: 633-637
• 221 Pletz MW, Ewig S, Rohde G. et al. Impact of pneumococcal vaccination in children on serotype distribution in adult community-acquired pneumonia using the serotype-specific multiplex urinary antigen detection assay. Vaccine 2016; 34: 2342-2348
• 222 Ewig S, Pletz M, Salzberger B. Empfehlungen zur Pneumokokken-Impfung der Senioren und Patienten mit Komorbiditäten: STIKO im Widerspruch zu den S3-Leitlinien zur Behandlung und Prävention der ambulant erworbenen Pneumonie. Dtsch Arztebl 2017; 114: A-24-27
• 223 van der Linden M, Imöhl M. Persistent burden of invasive pneumococcal disease in adults in Germany. Poster bei ECCMID; 2017
• 224 Spruit MA, Singh SJ, Garvey C. et al. An official American Thoracic Society/European Respiratory Society statement: key concepts and advances in pulmonary rehabilitation. Am J Respir Crit Care Med 2013; 188: e13-64
• 225 Nici L, Donner C, Wouters E. et al. American Thoracic Society/European Respiratory Society statement on pulmonary rehabilitation. Am J Respir Crit Care Med 2006; 173: 1390-1413
• 226 Ries AL, Bauldoff GS, Carlin BW. et al. Pulmonary Rehabilitation: Joint ACCP/AACVPR Evidence-Based Clinical Practice Guidelines. Chest 2007; 131: 4S-42S
• 227 Lacasse Y, Brosseau L, Milne S. et al. Pulmonary rehabilitation for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2002; 3: CD003793
• 228 Maltais F, Bourbeau J, Shapiro S. et al. Effects of home-based pulmonary rehabilitation in patients with chronic obstructive pulmonary disease: a randomized trial. Ann Intern Med 2008; 149: 869-878
• 229 Casaburi R, Kukafka D, Cooper CB. et al. Improvement in exercise tolerance with the combination of tiotropium and pulmonary rehabilitation in patients with COPD. Chest 2005; 127: 809-817
• 230 Lacasse Y, Wong E, Guyatt GH. et al. Meta-analysis of respiratory rehabilitation in chronic obstructive pulmonary disease. Lancet 1996; 348: 1115-1119
• 231 Puhan M, Scharplatz M, Troosters T. et al. Pulmonary rehabilitation following exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2009; 1: CD005305
• 232 Lacasse Y, Goldstein R, Lasserson TJ. et al. Pulmonary rehabilitation for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2006; 4: CD003793
• 233 Egan C, Deering BM, Blake C. et al. Short term and long term effects of pulmonary rehabilitation on physical activity in COPD. Respir Med 2012; 106: 1671-1679
• 234 Behnke M, Taube C, Kirsten D. et al. Home-based exercise is capable of preserving hospital-based improvements in severe chronic obstructive pulmonary disease. Respir Med 2000; 94: 1184-1191
• 235 Finnerty JP, Keeping I, Bullough I. et al. The effectiveness of outpatient pulmonary rehabilitation in chronic lung disease: a randomized controlled trial. Chest 2001; 119: 1705-1710
• 236 Green RH, Singh SJ, Williams J. et al. A randomised controlled trial of four weeks versus seven weeks of pulmonary rehabilitation in chronic obstructive pulmonary disease. Thorax 2001; 56: 143-145
• 237 Esteban C, Quintana JM, Aburto M. et al. Impact of changes in physical activity on health-related quality of life among patients with COPD. Eur Respir J 2010; 36: 292-300
• 238 Garcia-Aymerich J, Lange P, Benet M. et al. Regular physical activity reduces hospital admission and mortality in chronic obstructive pulmonary disease: a population based cohort study. Thorax 2006; 61: 772-778
• 239 Fernández AM, Pascual J, Ferrando C. et al. Home-based pulmonary rehabilitation in very severe COPD: is it safe and useful?. J Cardiopulm Rehabil Prev 2009; 29: 325-331
• 240 National Institute for Health and Care Excellence. CG101: Management of chronic obstructive pulmonary disease in adults in primary and secondary care. Update 2014
• 241 Young P, Dewse M, Fergusson W. et al. Respiratory rehabilitation in chronic obstructive pulmonary disease: predictors of nonadherence. Eur Respir J 1999; 13: 855-859
• 242 World Health Organization (WHO). International Classification of Functioning, Disability and Health (ICF). Geneva; 2001 http://www.3.who.int/icf/icftemplate.cfm
• 243 Richtlinien des Gemeinsamen Bundesausschusses über Leistungen zur medizinischen Rehabilitation (Rehabilitations-Richtlinien) nach § 92 Abs. 1 Satz 2 Nr. 8 SGB V in der Fassung vom 16. März 2004 (BAnz. S. 6769). http://www.aerzteblatt.de/pdf.asp?id=41621
• 244 American College of Chest Physicians. American Association of Cardiovascular and Pulmonary Rehabilitation. Pulmonary rehabilitation: joint ACCP/AACVPR evidence-based guidelines. ACCP/AACVPR Pulmonary Rehabilitation Guidelines Panel. Chest 1997; 112: 1363-1396
• 245 Verband deutscher rentenversicherungsträger (VDR). Reha-Kommission Krankheitsspezifische Konzepte. In: VDR, Reha Kommission. (eds.). Kommission zur Weiterentwicklung der Rehabilitation in der gesetzlichen Rentenversicherung. Abschlussberichte. Band III, Teilband 2, Frankfurt: VDR; 1991: 483-484
• 246 Bundesversicherungsanstalt für Angestellte (BfA). Leitlinien zur Rehabilitationsbedürftigkeit bei Krankheiten der Atmungsorgane – für den Beratungsärztlichen Dienst der BfA. 2004 http://www.bfa.de
• 247 Medizinischer Dienst der Spitzenverbände der Krankenkassen e.V. (MDS). Begutachtungs-Richtlinien Vorsorge und Rehabilitation. 2001
• 248 Mahler DA. Pulmonary rehabilitation. Chest 1998; 113: 263S-268S
• 249 Troosters T, Casaburi R, Gosselink R. et al. Pulmonary rehabilitation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2005; 172: 19-38
• 250 Puhan MA, Büsching G, Schünemann HJ. et al. Interval versus continuous high-intensity exercise in chronic obstructive pulmonary disease: a randomized trial. Ann Intern Med 2006; 145: 816-825
• 251 Vogiatzis I, Nanas S, Roussos C. Interval training as an alternative modality to continuous exercise in patients with COPD. Eur Respir J 2002; 20: 12-19
• 252 Honeyman P, Barr P, Stubbing DG. Effect of a walking aid on disability, oxygenation, and breathlessness in patients with chronic airflow limitation. J Cardiopulm Rehabil 1996; 16: 63-67
• 253 Palange P, Valli G, Onorati P. et al. Effect of heliox on lung dynamic hyperinflation, dyspnea, and exercise endurance capacity in COPD patients. J Appl Physiol 2004; 97: 1637-1642
• 254 Belman MJ, Botnick WC, Nathan SD. et al. Ventilatory load characteristics during ventilatory muscle training. Am J Respir Crit Care Med 1994; 149: 925-929
• 255 Lötters F, van Tol B, Kwakkel G. et al. Effects of controlled inspiratory muscle training in patients with COPD: a meta-analysis. Eur Respir J 2002; 20: 570-576
• 256 Magadle R, McConnell AK, Beckerman M. et al. Inspiratory muscle training in pulmonary rehabilitation program in COPD patients. Respir Med 2007; 101: 1500-1505
• 257 O'Brien K, Geddes EL, Reid WD. et al. Inspiratory muscle training compared with other rehabilitation interventions in chronic obstructive pulmonary disease: a systematic review update. J Cardiopulm Rehabil Prev 2008; 28: 128-141
• 258 Spielmanns M, Göhl O, Schultz K. et al. [Lung exercise: outpatient exercise program has long-term benefits on COPD]. Dtsch Med Wochenschr 2015; 140: 1001-1005
• 259 Worth H, Meyer A, Folgering H. et al. [Recommendations of the German Respiratory League on sports and physical training for patients with obstructive respiratory tract diseases]. Pneumologie 2000; 54: 61-67
• 260 Gloeckl R, Heinzelmann I, Baeuerle S. et al. Effects of whole body vibration in patients with chronic obstructive pulmonary disease – a randomized controlled trial. Respir Med 2012; 106: 75-83
• 261 Pleguezuelos E, Pérez ME, Guirao L. et al. Effects of whole body vibration training in patients with severe chronic obstructive pulmonary disease. Respirology 2013; 18: 1028-1034
• 262 Dhein Y, Münks-Lederer C, Worth H. [Evaluation of a structured education programme for patients with COPD under outpatient conditions – a pilot study]. Pneumologie 2003; 57: 591-597
• 263 Worth H, Dhein Y. Does patient education modify behaviour in the management of COPD?. Patient Educ Couns 2004; 52: 267-270
• 264 Bourbeau J, Julien M, Maltais F. et al. Reduction of hospital utilization in patients with chronic obstructive pulmonary disease: a disease-specific self-management intervention. Arch Intern Med 2003; 163: 585-591
• 265 Gadoury MA, Schwartzman K, Rouleau M. et al. Self-management reduces both short- and long-term hospitalisation in COPD. Eur Respir J 2005; 26: 853-857
• 266 Au DH, Udris EM, Engelberg RA. et al. A randomized trial to improve communication about end-of-life care among patients with COPD. Chest 2012; 141: 726-735
• 267 Sudore RL, Fried TR. Redefining the “planning” in advance care planning: preparing for end-of-life decision making. Ann Intern Med 2010; 153: 256-261
• 268 Weise S, Kardos P, Pfeiffer-Kascha D. Empfehlungen zur physiotherapeutischen Atemtherapie. 2.. Aufl. Oberhaching/München: Dustri Verlag Dr. Karl Feistle; 2008
• 269 Bhatt SP, Luqman-Arafath TK, Gupta AK. et al. Volitional pursed lips breathing in patients with stable chronic obstructive pulmonary disease improves exercise capacity. Chron Respir Dis 2013; 10: 5-10
• 270 Yamaguti WP, Claudino RC, Neto AP. et al. Diaphragmatic breathing training program improves abdominal motion during natural breathing in patients with chronic obstructive pulmonary disease: a randomized controlled trial. Arch Phys Med Rehabil 2012; 93: 571-577
• 271 Ides K, Vissers D, Vissers D. et al. Airway clearance in COPD: need for a breath of fresh air? A systematic review. COPD 2011; 8: 196-205
• 272 Borge CR, Hagen KB, Mengshoel AM. et al. Effects of controlled breathing exercises and respiratory muscle training in people with chronic obstructive pulmonary disease: results from evaluating the quality of evidence in systematic reviews. BMC Pulm Med 2014; 14: 184
• 273 Cegla UH, Retzow A. [Physical therapy with VRP1 in chronic obstructive respiratory tract diseases - results of a multicenter comparative study]. Pneumologie 1993; 47: 636-639
• 274 Cegla UH, Bautz M, Fröde G. et al. [Physical therapy in patients with COPD and tracheobronchial instability – comparison of 2 oscillating PEP systems (RC-Cornet, VRP1 Desitin). Results of a randommized prospective study of 90 patients]. Pneumologie 1997; 51: 129-136
• 275 Ferreira IM, Brooks D, White J. et al. Nutritional supplementation for stable chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2012; 12: CD000998
• 276 Ekström M, Nilsson F, Abernethy AA. et al. Effects of opioids on breathlessness and exercise capacity in chronic obstructive pulmonary disease. A systematic review. Ann Am Thorac Soc 2015; 12: 1079-1092
• 277 Rocker GM, Simpson AC, Joanne Young BHSc. et al. Opioid therapy for refractory dyspnea in patients with advanced chronic obstructive pulmonary disease: patients' experiences and outcomes. CMAJ open 2013; 1: E27-36
• 278 Marciniuk DD, Goodridge D, Hernandez P. et al. Managing dyspnea in patients with advanced chronic obstructive pulmonary disease: a Canadian Thoracic Society clinical practice guideline. Can Respir J 2011; 18: 69-78
• 279 Vieira PJ, Chiappa AM, Cipriano G. et al. Neuromuscular electrical stimulation improves clinical and physiological function in COPD patients. Respir Med 2014; 108: 609-620
• 280 Uronis HE, Ekström MP, Currow DC. et al. Oxygen for relief of dyspnoea in people with chronic obstructive pulmonary disease who would not qualify for home oxygen: a systematic review and meta-analysis. Thorax 2015; 70: 492-494
• 281 Higginson IJ, Bausewein C, Reilly CC. et al. An integrated palliative and respiratory care service for patients with advanced disease and refractory breathlessness: a randomised controlled trial. Lancet Respir Med 2014; 2: 979-987
• 282 Yohannes AM, Alexopoulos GS. Depression and anxiety in patients with COPD. Eur Respir Rev 2014; 23: 345-349
• 283 Farver-Vestergaard I, Jacobsen D, Zachariae R. Efficacy of psychosocial interventions on psychological and physical health outcomes in chronic obstructive pulmonary disease: a systematic review and meta-analysis. Psychother Psychosom 2015; 84: 37-50
• 284 Kruis AL, Smidt N, Assendelft WJ. et al. Integrated disease management interventions for patients with chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2013; 10: CD009437
• 285 Kruis AL, Boland MR, Assendelft WJ. et al. Effectiveness of integrated disease management for primary care chronic obstructive pulmonary disease patients: results of cluster randomised trial. BMJ 2014; 349: g5392
• 286 Disler RT, Green A, Luckett T. et al. Experience of advanced chronic obstructive pulmonary disease: metasynthesis of qualitative research. J Pain Symptom Manage 2014; 48: 1182-1199
• 287 Elkington H, White P, Addington-Hall J. et al. The last year of life of COPD: a qualitative study of symptoms and services. Respir Med 2004; 98: 439-445
• 288 Jennings AL, Davies AN, Higgins JP. et al. A systematic review of the use of opioids in the management of dyspnoea. Thorax 2002; 57: 939-944
• 289 Steinkamp G, Dierkesmann R, Gillissen A. et al. [COPD and psychopathology: a review]. Pneumologie 2005; 59: 819-830
• 290 WHO Expert Committee. Cancer pain relief and palliative care. Report of a WHO Expert Committee. World Health Organ Tech Rep Ser 1990; 804: 1-75
• 291 Halpin DMG, Sermark DA, Seamark CJ. Palliative and end -of life-care for patients with respiratory disease. Eur Respir Monograph 2009; 43: 327-353
• 292 Weber C, Stirnemann J, Herrmann FR. et al. Can early introduction of specialized palliative care limit intensive care, emergency and hospital admissions in patients with severe and very severe COPD? A randomized study. BMC Palliat Care 2014; 13: 47
• 293 Ek K, Andershed B, Sahlberg-Blom E. et al. “The unpredictable death” – The last year of life for patients with advanced COPD: Relatives' stories. Palliat Support Care 2015; 13: 1213-1222
• 294 Mehran RJ, Deslauriers J. Indications for surgery and patient work-up for bullectomy. Chest Surg Clin N Am 1995; 5: 717-734
• 295 Hughes JA, MacArthur AM, Hutchison DC. et al. Long term changes in lung function after surgical treatment of bullous emphysema in smokers and ex-smokers. Thorax 1984; 39: 140-142
• 296 Martinez FJ, de Oca MM, Whyte RI. et al. Lung-volume reduction improves dyspnea, dynamic hyperinflation, and respiratory muscle function. Am J Respir Crit Care Med 1997; 155: 1984-1990
• 297 Fessler HE, Permutt S. Lung volume reduction surgery and airflow limitation. Am J Respir Crit Care Med 1998; 157: 715-722
• 298 Naunheim KS, Wood DE, Mohsenifar Z. et al. Long-term follow-up of patients receiving lung-volume-reduction surgery versus medical therapy for severe emphysema by the National Emphysema Treatment Trial Research Group. Ann Thorac Surg 2006; 82: 431-443
• 299 Christie JD, Edwards LB, Kucheryavaya AY. et al. The Registry of the International Society for Heart and Lung Transplantation: twenty-seventh official adult lung and heart-lung transplant report 2010. J Heart Lung Transplant 2010; 29: 1104-1118
• 300 Shah PL, Slebos DJ, Cardoso PF. et al. Bronchoscopic lung-volume reduction with Exhale airway stents for emphysema (EASE trial): randomised, sham-controlled, multicentre trial. Lancet 2011; 378: 997-1005
• 301 Come CE, Kramer MR, Dransfield MT. et al. A randomised trial of lung sealant versus medical therapy for advanced emphysema. Eur Respir J 2015; 46: 651-662
• 302 Herth FJ, Valipour A, Shah PL. et al. Segmental volume reduction using thermal vapour ablation in patients with severe emphysema: 6-month results of the multicentre, parallel-group, open-label, randomised controlled STEP-UP trial. Lancet Respir Med 2016; 4: 185-193
• 303 Shah PL, Gompelmann D, Valipour A. et al. Thermal vapour ablation to reduce segmental volume in patients with severe emphysema: STEP-UP 12 month results. Lancet Respir Med 2016; 4: e44-e45
• 304 Sciurba FC, Ernst A, Herth FJ. et al. A randomized study of endobronchial valves for advanced emphysema. N Engl J Med 2010; 363: 1233-1244
• 305 Herth FJ, Noppen M, Valipour A. et al. Efficacy predictors of lung volume reduction with Zephyr valves in a European cohort. Eur Respir J 2012; 39: 1334-1342
• 306 Ninane V, Geltner C, Bezzi M. et al. Multicentre European study for the treatment of advanced emphysema with bronchial valves. Eur Respir J 2012; 39: 1319-1325
• 307 Davey C, Zoumot Z, Jordan S. et al. Bronchoscopic lung volume reduction with endobronchial valves for patients with heterogeneous emphysema and intact interlobar fissures (the BeLieVeR-HIFi trial): study design and rationale. Thorax 2015; 70: 288-290
• 308 Klooster K, ten Hacken NH, Hartman JE. et al. Endobronchial Valves for Emphysema without Interlobar Collateral Ventilation. N Engl J Med 2015; 373: 2325-2335
• 309 Valipour A, Slebos DJ, Herth F. et al. Endobronchial Valve Therapy in Patients with Homogeneous Emphysema. Results from the IMPACT Study. Am J Respir Crit Care Med 2016; 194: 1073-1082
• 310 Shah PL, Herth FJ. Current status of bronchoscopic lung volume reduction with endobronchial valves. Thorax 2014; 69: 280-286
• 311 Iftikhar IH, McGuire FR, Musani AI. Predictors of efficacy for endobronchial valves in bronchoscopic lung volume reduction: A meta-analysis. Chron Respir Dis 2014; 11: 237-245
• 312 Venuta F, Anile M, Diso D. et al. Long-term follow-up after bronchoscopic lung volume reduction in patients with emphysema. Eur Respir J 2012; 39: 1084-1089
• 313 Gompelmann D, Eberhardt R, Slebos DJ. et al. Diagnostic performance comparison of the Chartis System and high-resolution computerized tomography fissure analysis for planning endoscopic lung volume reduction. Respirology 2014; 19: 524-530
• 314 Gompelmann D, Benjamin N, Kontogianni K. et al. Clinical and radiological outcome following pneumothorax after endoscopic lung volume reduction with valves. Int J Chron Obstruct Pulmon Dis 2016; 11: 3093-3099
• 315 Valipour A, Slebos DJ, de Oliveira HG. et al. Expert statement: pneumothorax associated with endoscopic valve therapy for emphysema – potential mechanisms, treatment algorithm, and case examples. Respiration 2014; 87: 513-521
• 316 Herth FJ, Gompelmann D, Stanzel F. et al. Treatment of advanced emphysema with emphysematous lung sealant (AeriSeal^®). Respiration 2011; 82: 36-45
• 317 Deslee G, Klooster K, Hetzel M. et al. Lung volume reduction coil treatment for patients with severe emphysema: a European multicentre trial. Thorax 2014; 69: 980-986
• 318 Klooster K, Ten Hacken NH, Franz I. et al. Lung volume reduction coil treatment in chronic obstructive pulmonary disease patients with homogeneous emphysema: a prospective feasibility trial. Respiration 2014; 88: 116-125
• 319 Hartman JE, Klooster K, Gortzak K. et al. Long-term follow-up after bronchoscopic lung volume reduction treatment with coils in patients with severe emphysema. Respirology 2015; 20: 319-326
• 320 Snell GI, Hopkins P, Westall G. et al. A feasibility and safety study of bronchoscopic thermal vapor ablation: a novel emphysema therapy. Ann Thorac Surg 2009; 88: 1993-1998
• 321 Shah PL, Zoumot Z, Singh S. et al. Endobronchial coils for the treatment of severe emphysema with hyperinflation (RESET): a randomised controlled trial. Lancet Respir Med 2013; 1: 233-240
• 322 Deslée G, Mal H, Dutau H. et al. Lung Volume Reduction Coil Treatment vs Usual Care in Patients With Severe Emphysema: The REVOLENS Randomized Clinical Trial. JAMA 2016; 315: 175-184
• 323 Sciurba FC, Criner GJ, Strange C. et al. Effect of Endobronchial Coils vs Usual Care on Exercise Tolerance in Patients With Severe Emphysema: The RENEW Randomized Clinical Trial. JAMA 2016; 315: 2178-2189
• 324 Gottlieb J, Simon A, Welte T. Lungentransplantation. Pneumologe 2005; 2: 131-141
• 325 Weill D, Benden C, Corris PA. et al. A consensus document for the selection of lung transplant candidates: 2014 – an update from the Pulmonary Transplantation Council of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant 2015; 34: 1-15
• 326 Yusen RD, Edwards LB, Kucheryavaya AY. et al. The registry of the International Society for Heart and Lung Transplantation: thirty-first adult lung and heart-lung transplant report – 2014; focus theme: retransplantation. J Heart Lung Transplant 2014; 33: 1009-1024
• 327 Thabut G, Christie JD, Ravaud P. et al. Survival after bilateral versus single lung transplantation for patients with chronic obstructive pulmonary disease: a retrospective analysis of registry data. Lancet 2008; 371: 744-751
• 328 Richtlinien zur Transplantationsmedizin. http://www.bundesaerztekammer.de/richtlinien/richtlinien/transplantationsmedizin/
• 329 Gottlieb J, Smits J, Schramm R. et al. Lung Transplantation in Germany Since the Introduction of the Lung Allocation Score: A Retrospective Analysis. Dtsch Arztebl Int 2017; 114: 179-185
• 330 Schaffer JM, Singh SK, Reitz BA. et al. Single- vs double-lung transplantation in patients with chronic obstructive pulmonary disease and idiopathic pulmonary fibrosis since the implementation of lung allocation based on medical need. JAMA 2015; 313: 936-948
• 331 Ruttens D, Verleden SE, Goeminne PC. et al. Smoking resumption after lung transplantation: standardised screening and importance for long-term outcome. Eur Respir J 2014; 43: 300-303
• 332 Suhling H, Knuth C, Haverich A. et al. Employment after lung transplantation – a single-center cross-sectional study. Dtsch Arztebl Int 2015; 112: 213-219
• 333 Windisch W, Schönhofer B, Magnet FS. et al. [Diagnosis and Treatment of Diaphragmatic Dysfunction]. Pneumologie 2016; 70: 454-461
• 334 Roussos C. The failing ventilatory pump. Lung 1982; 160: 59-84
• 335 Windisch W. [Pathophysiology of respiratory muscle weakness]. Pneumologie 2008; 62: S18-22
• 336 Windisch W, Dreher M, Geiseler J. et al. [Guidelines for Non-Invasive and Invasive Home Mechanical Ventilation for Treatment of Chronic Respiratory Failure – Update 2017]. Pneumologie 2017; 71: 722-795
• 337 Levine BE, Bigelow DB, Hamstra RD. et al. The role of long-term continuous oxygen administration in patients with chronic airway obstruction with hypoxemia. Ann Intern Med 1967; 66: 639-650
• 338 Stoller JK, Panos RJ, Krachman S. et al. Oxygen therapy for patients with COPD: current evidence and the long-term oxygen treatment trial. Chest 2010; 138: 179-187
• 339 Magnussen H, Kirsten AM, Köhler D. et al. [Guidelines for long-term oxygen therapy. German Society for Pneumology and Respiratory Medicine]. Pneumologie 2008; 62: 748-756
• 340 Magnussen H, Hauck RW, Worth H. et al. [Statement to long term oxygen therapy]. Pneumologie 2014; 68: 591-593
• 341 Nocturnal Oxygen Therapy Trial Group. Continuous or nocturnal oxygen therapy in hypoxemic chronic obstructive lung disease: a clinical trial. Ann Intern Med 1980; 93: 391-398
• 342 Medical Research Council Working Party. Long term domiciliary oxygen therapy in chronic hypoxic cor pulmonale complicating chronic bronchitis and emphysema. Report of the Medical Research Council Working Party. Lancet 1981; 1: 681-686
• 343 Long-Term Oxygen Treatment Trial Research Group, Albert RK, Au DH et al. A Randomized Trial of Long-Term Oxygen for COPD with Moderate Desaturation. N Engl J Med 2016; 375: 1617-1627
• 344 Hardinge M, Annandale J, Bourne S. et al. British Thoracic Society guidelines for home oxygen use in adults. Thorax 2015; 70: i1-43
• 345 Magnet FS, Schwarz SB, Callegari J. et al. Long-Term Oxygen Therapy: Comparison of the German and British Guidelines. Respiration 2017; 93: 253-263
• 346 Schönhofer B, Geiseler J, Dellweg D. et al. [Prolonged weaning: S2k-guideline published by the German Respiratory Society]. Pneumologie 2014; 68: 19-75
• 347 Windisch W, Storre JH, Köhnlein T. Nocturnal non-invasive positive pressure ventilation for COPD. Expert Rev Respir Med 2015; 9: 295-308
• 348 Struik FM, Lacasse Y, Goldstein RS. et al. Nocturnal noninvasive positive pressure ventilation in stable COPD: a systematic review and individual patient data meta-analysis. Respir Med 2014; 108: 329-337
• 349 Gay PC, Hubmayr RD, Stroetz RW. Efficacy of nocturnal nasal ventilation in stable, severe chronic obstructive pulmonary disease during a 3-month controlled trial. Mayo Clin Proc 1996; 71: 533-542
• 350 Strumpf DA, Millman RP, Carlisle CC. et al. Nocturnal positive-pressure ventilation via nasal mask in patients with severe chronic obstructive pulmonary disease. Am Rev Respir Dis 1991; 144: 1234-1239
• 351 Casanova C, Celli BR, Tost L. et al. Long-term controlled trial of nocturnal nasal positive pressure ventilation in patients with severe COPD. Chest 2000; 118: 1582-1590
• 352 Meecham Jones DJ, Paul EA, Jones PW. et al. Nasal pressure support ventilation plus oxygen compared with oxygen therapy alone in hypercapnic COPD. Am J Respir Crit Care Med 1995; 152: 538-544
• 353 Clini E, Sturani C, Rossi A. et al. The Italian multicentre study on noninvasive ventilation in chronic obstructive pulmonary disease patients. Eur Respir J 2002; 20: 529-538
• 354 McEvoy RD, Pierce RJ, Hillman D. et al. Nocturnal non-invasive nasal ventilation in stable hypercapnic COPD: a randomised controlled trial. Thorax 2009; 64: 561-566
• 355 Windisch W, Haenel M, Storre JH. et al. High-intensity non-invasive positive pressure ventilation for stable hypercapnic COPD. Int J Med Sci 2009; 6: 72-76
• 356 Windisch W. Noninvasive positive pressure ventilation in COPD. Breathe 2011; 8: 114-123
• 357 Windisch W, Kostić S, Dreher M. et al. Outcome of patients with stable COPD receiving controlled noninvasive positive pressure ventilation aimed at a maximal reduction of PaCO2. Chest 2005; 128: 657-662
• 358 Windisch W. Impact of home mechanical ventilation on health-related quality of life. Eur Respir J 2008; 32: 1328-1336
• 359 Dreher M, Storre JH, Schmoor C. et al. High-intensity versus low-intensity non-invasive ventilation in patients with stable hypercapnic COPD: a randomised crossover trial. Thorax 2010; 65: 303-308
• 360 Köhnlein T, Windisch W, Köhler D. et al. Non-invasive positive pressure ventilation for the treatment of severe stable chronic obstructive pulmonary disease: a prospective, multicentre, randomised, controlled clinical trial. Lancet Respir Med 2014; 2: 698-705
• 361 Struik FM, Sprooten RT, Kerstjens HA. et al. Nocturnal non-invasive ventilation in COPD patients with prolonged hypercapnia after ventilatory support for acute respiratory failure: a randomised, controlled, parallel-group study. Thorax 2014; 69: 826-834
• 362 Murphy PB, Rehal S, Arbane G. et al. Effect of Home Noninvasive Ventilation With Oxygen Therapy vs Oxygen Therapy Alone on Hospital Readmission or Death After an Acute COPD Exacerbation: A Randomized Clinical Trial. JAMA 2017; 317: 2177-2186
• 363 Bischoff EW, Akkermans R, Bourbeau J. et al. Comprehensive self management and routine monitoring in chronic obstructive pulmonary disease patients in general practice: randomised controlled trial. BMJ 2012; 345: e7642
• 364 Leidy NK, Murray LT, Jones P. et al. Performance of the EXAcerbations of chronic pulmonary disease tool patient-reported outcome measure in three clinical trials of chronic obstructive pulmonary disease. Ann Am Thorac Soc 2014; 11: 316-325
• 365 Jones PW, Lamarca R, Chuecos F. et al. Characterisation and impact of reported and unreported exacerbations: results from ATTAIN. Eur Respir J 2014; 44: 1156-1165
• 366 Rodriguez-Roisin R. Toward a consensus definition for COPD exacerbations. Chest 2000; 117: 398S-401S
• 367 Thompson WH, Nielson CP, Carvalho P. et al. Controlled trial of oral prednisone in outpatients with acute COPD exacerbation. Am J Respir Crit Care Med 1996; 154: 407-412
• 368 Niewoehner DE, Erbland ML, Deupree RH. et al. Effect of systemic glucocorticoids on exacerbations of chronic obstructive pulmonary disease. Department of Veterans Affairs Cooperative Study Group. N Engl J Med 1999; 340: 1941-1947
• 369 Aaron SD, Vandemheen KL, Hebert P. et al. Outpatient oral prednisone after emergency treatment of chronic obstructive pulmonary disease. N Engl J Med 2003; 348: 2618-2625
• 370 Davies L, Angus RM, Calverley PM. Oral corticosteroids in patients admitted to hospital with exacerbations of chronic obstructive pulmonary disease: a prospective randomised controlled trial. Lancet 1999; 354: 456-460
• 371 Alía I, de la Cal MA, Esteban A. et al. Efficacy of corticosteroid therapy in patients with an acute exacerbation of chronic obstructive pulmonary disease receiving ventilatory support. Arch Intern Med 2011; 171: 1939-1946
• 372 Leuppi JD, Schuetz P, Bingisser R. et al. Short-term vs conventional glucocorticoid therapy in acute exacerbations of chronic obstructive pulmonary disease: the REDUCE randomized clinical trial. JAMA 2013; 309: 2223-2231
• 373 Walters JA, Tan DJ, White CJ. et al. Different durations of corticosteroid therapy for exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2014; 12: CD006897
• 374 de Jong YP, Uil SM, Grotjohan HP. et al. Oral or IV prednisolone in the treatment of COPD exacerbations: a randomized, controlled, double-blind study. Chest 2007; 132: 1741-1747
• 375 Ceviker Y, Sayiner A. Comparison of two systemic steroid regimens for the treatment of COPD exacerbations. Pulm Pharmacol Ther 2014; 27: 179-183
• 376 Maltais F, Ostinelli J, Bourbeau J. et al. Comparison of nebulized budesonide and oral prednisolone with placebo in the treatment of acute exacerbations of chronic obstructive pulmonary disease: a randomized controlled trial. Am J Respir Crit Care Med 2002; 165: 698-703
• 377 Gunen H, Hacievliyagil SS, Yetkin O. et al. The role of nebulised budesonide in the treatment of exacerbations of COPD. Eur Respir J 2007; 29: 660-667
• 378 Ställberg B, Selroos O, Vogelmeier C. et al. Budesonide/formoterol as effective as prednisolone plus formoterol in acute exacerbations of COPD. A double-blind, randomised, non-inferiority, parallel-group, multicentre study. Respir Res 2009; 10: 11
• 379 Duffy N, Walker P, Diamantea F. et al. Intravenous aminophylline in patients admitted to hospital with non-acidotic exacerbations of chronic obstructive pulmonary disease: a prospective randomised controlled trial. Thorax 2005; 60: 713-717
• 380 Monsó E, Ruiz J, Rosell A. et al. Bacterial infection in chronic obstructive pulmonary disease. A study of stable and exacerbated outpatients using the protected specimen brush. Am J Respir Crit Care Med 1995; 152: 1316-1320
• 381 Sethi S, Sethi R, Eschberger K. et al. Airway bacterial concentrations and exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007; 176: 356-361
• 382 Sethi S, Evans N, Grant BJ. et al. New strains of bacteria and exacerbations of chronic obstructive pulmonary disease. N Engl J Med 2002; 347: 465-471
• 383 Anthonisen NR, Manfreda J, Warren CP. et al. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med 1987; 106: 196-204
• 384 Saint S, Bent S, Vittinghoff E. et al. Antibiotics in chronic obstructive pulmonary disease exacerbations. A meta-analysis. JAMA 1995; 273: 957-960
• 385 Jørgensen AF, Coolidge J, Pedersen PA. et al. Amoxicillin in treatment of acute uncomplicated exacerbations of chronic bronchitis. A double-blind, placebo-controlled multicentre study in general practice. Scand J Prim Health Care 1992; 10: 7-11
• 386 Sachs AP, Koëter GH, Groenier KH. et al. Changes in symptoms, peak expiratory flow, and sputum flora during treatment with antibiotics of exacerbations in patients with chronic obstructive pulmonary disease in general practice. Thorax 1995; 50: 758-763
• 387 Llor C, Moragas A, Bayona C. et al. Efficacy of anti-inflammatory or antibiotic treatment in patients with non-complicated acute bronchitis and discoloured sputum: randomised placebo controlled trial. BMJ 2013; 347: f5762
• 388 Llor C, Moragas A, Hernández S. et al. Efficacy of antibiotic therapy for acute exacerbations of mild to moderate chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2012; 186: 716-723
• 389 Daniels JM, Snijders D, de Graaff CS. et al. Antibiotics in addition to systemic corticosteroids for acute exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2010; 181: 150-157
• 390 Nouira S, Marghli S, Belghith M. et al. Once daily oral ofloxacin in chronic obstructive pulmonary disease exacerbation requiring mechanical ventilation: a randomised placebo-controlled trial. Lancet 2001; 358: 2020-2025
• 391 Fagon JY, Chastre J, Trouillet JL. et al. Characterization of distal bronchial microflora during acute exacerbation of chronic bronchitis. Use of the protected specimen brush technique in 54 mechanically ventilated patients. Am Rev Respir Dis 1990; 142: 1004-1008
• 392 Ram FS, Rodriguez-Roisin R, Granados-Navarrete A. et al. Antibiotics for exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2006; 2: CD004403
• 393 Quon BS, Gan WQ, Sin DD. Contemporary management of acute exacerbations of COPD: a systematic review and metaanalysis. Chest 2008; 133: 756-766
• 394 Ram FS, Rodriguez-Roisin R, Granados-Navarrete A. et al. WITHDRAWN: Antibiotics for exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2011; 1: CD004403
• 395 Vollenweider DJ, Jarrett H, Steurer-Stey CA. et al. Antibiotics for exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2012; 12: CD010257
• 396 Stolz D, Christ-Crain M, Bingisser R. et al. Antibiotic treatment of exacerbations of COPD: a randomized, controlled trial comparing procalcitonin-guidance with standard therapy. Chest 2007; 131: 9-19
• 397 Stockley RA, O'Brien C, Pye A. et al. Relationship of sputum color to nature and outpatient management of acute exacerbations of COPD. Chest 2000; 117: 1638-1645
• 398 Soler N, Agustí C, Angrill J. et al. Bronchoscopic validation of the significance of sputum purulence in severe exacerbations of chronic obstructive pulmonary disease. Thorax 2007; 62: 29-35
• 399 Miravitlles M, Moragas A, Hernández S. et al. Is it possible to identify exacerbations of mild to moderate COPD that do not require antibiotic treatment?. Chest 2013; 144: 1571-1577
• 400 Brusse-Keizer MG, Grotenhuis AJ, Kerstjens HA. et al. Relation of sputum colour to bacterial load in acute exacerbations of COPD. Respir Med 2009; 103: 601-606
• 401 Soler N, Esperatti M, Ewig S. et al. Sputum purulence-guided antibiotic use in hospitalised patients with exacerbations of COPD. Eur Respir J 2012; 40: 1344-1353
• 402 Miravitlles M, Kruesmann F, Haverstock D. et al. Sputum colour and bacteria in chronic bronchitis exacerbations: a pooled analysis. Eur Respir J 2012; 39: 1354-1360
• 403 Peng C, Tian C, Zhang Y. et al. C-reactive protein levels predict bacterial exacerbation in patients with chronic obstructive pulmonary disease. Am J Med Sci 2013; 345: 190-194
• 404 Clark TW, Medina MJ, Batham S. et al. C-reactive protein level and microbial aetiology in patients hospitalised with acute exacerbation of COPD. Eur Respir J 2015; 45: 76-86
• 405 Santos S, Marin A, Serra-Batlles J. et al. Treatment of patients with COPD and recurrent exacerbations: the role of infection and inflammation. Int J Chron Obstruct Pulmon Dis 2016; 11: 515-525
• 406 DeAbate CA, Mathew CP, Warner JH. et al. The safety and efficacy of short course (5-day) moxifloxacin vs. azithromycin in the treatment of patients with acute exacerbation of chronic bronchitis. Respir Med 2000; 94: 1029-1037
• 407 Chodosh S, DeAbate CA, Haverstock D. et al. Short-course moxifloxacin therapy for treatment of acute bacterial exacerbations of chronic bronchitis. The Bronchitis Study Group. Respir Med 2000; 94: 18-27
• 408 Masterton RG, Burley CJ. Randomized, double-blind study comparing 5- and 7-day regimens of oral levofloxacin in patients with acute exacerbation of chronic bronchitis. Int J Antimicrob Agents 2001; 18: 503-512
• 409 Swanson RN, Lainez-Ventosilla A, De Salvo MC. et al. Once-daily azithromycin for 3 days compared with clarithromycin for 10 days for acute exacerbation of chronic bronchitis: a multicenter, double-blind, randomized study. Treat Respir Med 2005; 4: 31-39
• 410 Nouira S, Marghli S, Besbes L. et al. Standard versus newer antibacterial agents in the treatment of severe acute exacerbation of chronic obstructive pulmonary disease: a randomized trial of trimethoprim-sulfamethoxazole versus ciprofloxacin. Clin Infect Dis 2010; 51: 143-149
• 411 Wilson R, Anzueto A, Miravitlles M. et al. Moxifloxacin versus amoxicillin/clavulanic acid in outpatient acute exacerbations of COPD: MAESTRAL results. Eur Respir J 2012; 40: 17-27
• 412 Wilson R, Allegra L, Huchon G. et al. Short-term and long-term outcomes of moxifloxacin compared to standard antibiotic treatment in acute exacerbations of chronic bronchitis. Chest 2004; 125: 953-964
• 413 Hutchison DC, Flenley DC, Donald KW. Controlled Oxygen Therapy in Respiratory Failure. Br Med J 1964; 2: 1159-1166
• 414 DeGaute JP, Domenighetti G, Naeije R. et al. Oxygen delivery in acute exacerbation of chronic obstructive pulmonary disease. Effects of controlled oxygen therapy. Am Rev Respir Dis 1981; 124: 26-30
• 415 Moloney ED, Kiely JL, McNicholas WT. Controlled oxygen therapy and carbon dioxide retention during exacerbations of chronic obstructive pulmonary disease. Lancet 2001; 357: 526-528
• 416 Storre JH, Windisch W. High-Flow-Sauerstoff in der Therapie der akuten respiratorischen Insuffizienz. Der Pneumologe 2016; 13: 308-319
• 417 Frat JP, Thille AW, Mercat A. et al. High-flow oxygen through nasal cannula in acute hypoxemic respiratory failure. N Engl J Med 2015; 372: 2185-2196
• 418 Lee CC, Mankodi D, Shaharyar S. et al. High flow nasal cannula versus conventional oxygen therapy and non-invasive ventilation in adults with acute hypoxemic respiratory failure: A systematic review. Respir Med 2016; 121: 100-108
• 419 Antonelli M, Conti G, Rocco M. et al. A comparison of noninvasive positive-pressure ventilation and conventional mechanical ventilation in patients with acute respiratory failure. N Engl J Med 1998; 339: 429-435
• 420 Westhoff M, Schönhofer B, Neumann P. et al. [Noninvasive Mechanical Ventilation in Acute Respiratory Failure]. Pneumologie 2015; 69: 719-756
• 421 Brochard L, Mancebo J, Wysocki M. et al. Noninvasive ventilation for acute exacerbations of chronic obstructive pulmonary disease. N Engl J Med 1995; 333: 817-822
• 422 Lightowler JV, Wedzicha JA, Elliott MW. et al. Non-invasive positive pressure ventilation to treat respiratory failure resulting from exacerbations of chronic obstructive pulmonary disease: Cochrane systematic review and meta-analysis. BMJ 2003; 326: 185
• 423 Moretti M, Cilione C, Tampieri A. et al. Incidence and causes of non-invasive mechanical ventilation failure after initial success. Thorax 2000; 55: 819-825
• 424 Bayarassou AH, Storre JH, Windisch W. Common mistakes leading to NIV failure. Minerva Pneumol 2013; 52: 39-53
• 425 Chandra D, Stamm JA, Taylor B. et al. Outcomes of noninvasive ventilation for acute exacerbations of chronic obstructive pulmonary disease in the United States, 1998-2008. Am J Respir Crit Care Med 2012; 185: 152-159
• 426 Karagiannidis C, Brodie D, Strassmann S. et al. Extracorporeal membrane oxygenation: evolving epidemiology and mortality. Intensive Care Med 2016; 42: 889-896
• 427 Karagiannidis C, Philipp A, Strassmann S. et al. [Extracorporeal CO2 Elimination (ECCO2R) for Hypercapnic Respiratory Failure: From Pathophysiology to Clinical Application]. Pneumologie 2017; 71: 215-220
• 428 Braune S, Sieweke A, Brettner F. et al. The feasibility and safety of extracorporeal carbon dioxide removal to avoid intubation in patients with COPD unresponsive to noninvasive ventilation for acute hypercapnic respiratory failure (ECLAIR study): multicentre case-control study. Intensive Care Med 2016; 42: 1437-1444
• 429 Del Sorbo L, Pisani L, Filippini C. et al. Extracorporeal Co2 removal in hypercapnic patients at risk of noninvasive ventilation failure: a matched cohort study with historical control. Crit Care Med 2015; 43: 120-127
• 430 Kluge S, Braune SA, Engel M. et al. Avoiding invasive mechanical ventilation by extracorporeal carbon dioxide removal in patients failing noninvasive ventilation. Intensive Care Med 2012; 38: 1632-1639
• 431 Trahanas JM, Lynch WR, Bartlett RH. Extracorporeal Support for Chronic Obstructive Pulmonary Disease: A Bright Future. J Intensive Care Med 2017; 32: 411-420
• 432 Hartl S, Lopez-Campos JL, Pozo-Rodriguez F. et al. Risk of death and readmission of hospital-admitted COPD exacerbations: European COPD Audit. Eur Respir J 2016; 47: 113-121
• 433 Donaldson GC, Hurst JR, Smith CJ. et al. Increased risk of myocardial infarction and stroke following exacerbation of COPD. Chest 2010; 137: 1091-1097
• 434 Vanfleteren LE, Spruit MA, Groenen M. et al. Clusters of comorbidities based on validated objective measurements and systemic inflammation in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2013; 187: 728-735
• 435 Nussbaumer-Ochsner Y, Rabe KF. Systemic manifestations of COPD. Chest 2011; 139: 165-173
• 436 Decramer M, Janssens W. Chronic obstructive pulmonary disease and comorbidities. Lancet Respir Med 2013; 1: 73-83
• 437 Fabbri LM, Rabe KF. From COPD to chronic systemic inflammatory syndrome?. Lancet 2007; 370: 797-799
• 438 Triest FJ, Franssen FM, Spruit MA. et al. Poor agreement between chart-based and objectively identified comorbidities of COPD. Eur Respir J 2015; 46: 1492-1495
• 439 Chen W, Thomas J, Sadatsafavi M. et al. Risk of cardiovascular comorbidity in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. Lancet Respir Med 2015; 3: 631-639
• 440 Portegies ML, Lahousse L, Joos GF. et al. Chronic Obstructive Pulmonary Disease and the Risk of Stroke. The Rotterdam Study. Am J Respir Crit Care Med 2016; 193: 251-258
• 441 Sin DD, Anthonisen NR, Soriano JB. et al. Mortality in COPD: Role of comorbidities. Eur Respir J 2006; 28: 1245-1257
• 442 Mannino DM, Thorn D, Swensen A. et al. Prevalence and outcomes of diabetes, hypertension and cardiovascular disease in COPD. Eur Respir J 2008; 32: 962-969
• 443 Wedzicha JA, Brill SE, Allinson JP. et al. Mechanisms and impact of the frequent exacerbator phenotype in chronic obstructive pulmonary disease. BMC Med 2013; 11: 181
• 444 van Gestel YR, Hoeks SE, Sin DD. et al. Effect of statin therapy on mortality in patients with peripheral arterial disease and comparison of those with versus without associated chronic obstructive pulmonary disease. Am J Cardiol 2008; 102: 192-196
• 445 Janda S, Park K, FitzGerald JM. et al. Statins in COPD: a systematic review. Chest 2009; 136: 734-743
• 446 Short PM, Lipworth SI, Elder DH. et al. Effect of beta blockers in treatment of chronic obstructive pulmonary disease: a retrospective cohort study. BMJ 2011; 342: d2549
• 447 Quint JK, Herrett E, Bhaskaran K. et al. Effect of β blockers on mortality after myocardial infarction in adults with COPD: population based cohort study of UK electronic healthcare records. BMJ 2013; 347: f6650
• 448 Criner GJ, Connett JE, Aaron SD. et al. Simvastatin for the prevention of exacerbations in moderate-to-severe COPD. N Engl J Med 2014; 370: 2201-2210
• 449 Falk JA, Kadiev S, Criner GJ. et al. Cardiac disease in chronic obstructive pulmonary disease. Proc Am Thorac Soc 2008; 5: 543-548
• 450 Barr RG, Bluemke DA, Ahmed FS. et al. Percent emphysema, airflow obstruction, and impaired left ventricular filling. N Engl J Med 2010; 362: 217-227
• 451 Watz H, Waschki B, Meyer T. et al. Decreasing cardiac chamber sizes and associated heart dysfunction in COPD: role of hyperinflation. Chest 2010; 138: 32-38
• 452 Jörgensen K, Houltz E, Westfelt U. et al. Effects of lung volume reduction surgery on left ventricular diastolic filling and dimensions in patients with severe emphysema. Chest 2003; 124: 1863-1870
• 453 Stone IS, Barnes NC, James WY. et al. Lung Deflation and Cardiovascular Structure and Function in Chronic Obstructive Pulmonary Disease. A Randomized Controlled Trial. Am J Respir Crit Care Med 2016; 193: 717-726
• 454 Stolz D, Rasch H, Linka A. et al. A randomised, controlled trial of bosentan in severe COPD. Eur Respir J 2008; 32: 619-628
• 455 Blanco I, Gimeno E, Munoz PA. et al. Hemodynamic and gas exchange effects of sildenafil in patients with chronic obstructive pulmonary disease and pulmonary hypertension. Am J Respir Crit Care Med 2010; 181: 270-278
• 456 Minai OA, Chaouat A, Adnot S. Pulmonary hypertension in COPD: epidemiology, significance, and management: pulmonary vascular disease: the global perspective. Chest 2010; 137: 39S-51S
• 457 de-Torres JP, Wilson DO, Sanchez-Salcedo P. et al. Lung cancer in patients with chronic obstructive pulmonary disease. Development and validation of the COPD Lung Cancer Screening Score. Am J Respir Crit Care Med 2015; 191: 285-291
• 458 Kiri VA, Soriano J, Visick G. et al. Recent trends in lung cancer and its association with COPD: an analysis using the UK GP Research Database. Prim Care Respir J 2010; 19: 57-61
• 459 National Lung Screening Trial Research Team, Aberle DR, Adams AM et al. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med 2011; 365: 395-409
• 460 Young RP, Duan F, Chiles C. et al. Airflow Limitation and Histology Shift in the National Lung Screening Trial. The NLST-ACRIN Cohort Substudy. Am J Respir Crit Care Med 2015; 192: 1060-1067
• 461 Wille MM, Dirksen A, Ashraf H. et al. Results of the Randomized Danish Lung Cancer Screening Trial with Focus on High-Risk Profiling. Am J Respir Crit Care Med 2016; 193: 542-551
• 462 Herth FJ, Hoffmann H, Heussel CP. et al. [Lung cancer screening – Update 2014]. Pneumologie 2014; 68: 781-783
• 463 Graat-Verboom L, Wouters EF, Smeenk FW. et al. Current status of research on osteoporosis in COPD: a systematic review. Eur Respir J 2009; 34: 209-218
• 464 Graat-Verboom L, Smeenk FW, van den Borne BE. et al. Risk factors for osteoporosis in Caucasian patients with moderate chronic obstructive pulmonary disease: a case control study. Bone 2012; 50: 1234-1239
• 465 Maltais F, Decramer M, Casaburi R. et al. An official American Thoracic Society/European Respiratory Society statement: update on limb muscle dysfunction in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2014; 189: e15-62
• 466 Waschki B, Kirsten AM, Holz O. et al. Disease Progression and Changes in Physical Activity in Patients with Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med 2015; 192: 295-306
• 467 Marquis K, Maltais F, Duguay V. et al. The metabolic syndrome in patients with chronic obstructive pulmonary disease. J Cardiopulm Rehabil 2005; 25: 226-232
• 468 Watz H, Waschki B, Kirsten A. et al. The metabolic syndrome in patients with chronic bronchitis and COPD: frequency and associated consequences for systemic inflammation and physical inactivity. Chest 2009; 136: 1039-1046
• 469 Breyer MK, Spruit MA, Hanson CK. et al. Prevalence of metabolic syndrome in COPD patients and its consequences. PLoS One 2014; 9: e98013
• 470 Karch A, Vogelmeier C, Welte T. et al. The German COPD cohort COSYCONET: Aims, methods and descriptive analysis of the study population at baseline. Respir Med 2016; 114: 27-37
• 471 Panagioti M, Scott C, Blakemore A. et al. Overview of the prevalence, impact, and management of depression and anxiety in chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis 2014; 9: 1289-1306
• 472 Bang KM. Chronic obstructive pulmonary disease in nonsmokers by occupation and exposure: a brief review. Curr Opin Pulm Med 2015; 21: 149-154
• 473 Würtz ET, Schlünssen V, Malling TH. et al. Occupational COPD among Danish never-smokers: a population-based study. Occup Environ Med 2015; 72: 456-459
• 474 Preisser AM. Chronische obstruktive Atemwegserkrankung als Berufskrankheit. Der Pneumologe 2015; 12: 300-307
• 475 Brüske I, Thiering E, Heinrich J. et al. Biopersistent granular dust and chronic obstructive pulmonary disease: a systematic review and meta-analysis. PloS one 2013; 8: e80977
• 476 Omland O, Würtz ET, Aasen TB. et al. Occupational chronic obstructive pulmonary disease: a systematic literature review. Scand J Work Environ Health 2014; 40: 19-35
• 477 Szram J, Schofield SJ, Cosgrove MP. et al. Welding, longitudinal lung function decline and chronic respiratory symptoms: a systematic review of cohort studies. Eur Respir J 2013; 42: 1186-1193
• 478 May S, Romberger DJ, Poole JA. Respiratory health effects of large animal farming environments. J Toxicol Environ Health B Crit Rev 2012; 15: 524-541
• 479 Lai PS, Christiani DC. Long-term respiratory health effects in textile workers. Curr Opin Pulm Med 2013; 19: 152-157
• 480 Mehta AJ, Henneberger PK, Torén K. et al. Airflow limitation and changes in pulmonary function among bleachery workers. Eur Respir J 2005; 26: 133-139
• 481 DGUV (Deutsche Gesetzliche Unfallversicherung). Empfehlung für die Begutachtung der Berufskrankheiten der Nummern 1315 (ohne Alveolitis, 4301 und 4302 der Anlage zur Berufskrankheiten-Verordnung (BKV) – Reichenhaller Empfehlung. 2012 http://publikationen.dguv.de/dguv/pdf/10002/reichenhallneu.pdf
• 482 Nowak D. [Consensus paper for an expert opinion on the new occupational disease “chronic bronchitis/emphysema in pit-coal miners” (BK 4111)]. Pneumologie 1999; 53: 150-154
• 483 Baur X, Heutelbeck A, Kujath P. et al. [Prevention of occupational airway diseases: interdisciplinary guideline of the German Society for Occupational and Environmental Medicine]. Pneumologie 2011; 65: 263-282